Lupin and Gan​ & Lee ‌Announce strategic Partnership

On ‍Monday, December 29, 2023, ‍Lupin Limited announced a strategic partnership with Gan & Lee Pharmaceutical Co., Ltd. to bring⁣ Bofanglutide,a ​novel treatment for type 2 diabetes,to the⁤ Indian market.The agreement encompasses exclusive licensing, supply, and commercialization rights ‌for Bofanglutide within India.

This collaboration underscores⁢ Lupin’s commitment to addressing the escalating prevalence of metabolic diseases in⁤ india. According ‌to ⁢recent data,​ over 101 million adults in india are living ⁢with diabetes, and a notable portion of ⁣the population is either overweight or obese – approximately 146 million are overweight and about ⁤50 million are ⁣obese. ​diabetes already affects roughly 90 million adults in the country.

Bofanglutide: A Dosing advantage

A⁢ key differentiator of Bofanglutide is its convenient fortnightly (every two weeks) dosing ​schedule. Rajeev Sibal,‌ president, India region⁢ formulations, Lupin, highlighted this ⁢advantage, stating that it “reduces the number of injections by 50 per cent ‍while delivering outcomes and clinically proven efficacy ​that matches or ‌surpasses existing weekly formulations.” This‍ reduced⁢ injection frequency aims⁢ to improve patient adherence, a critical factor in effective diabetes management.

Nilesh Gupta,managing director,Lupin,emphasized the broader⁣ significance of the partnership,stating,”We are offering the best solutions for managing‌ chronic ⁤metabolic diseases like [diabetes],most urgent global health challenges. This partnership demonstrates our strategic ⁢focus on the GLP-1 class of drugs and ​highlights our dedication to delivering⁢ high-quality, ‌innovative therapies for our patients.”

Gan ⁢& Lee’s Global Expansion Strategy

Gan ⁢& Lee executives indicated that the agreement with Lupin is part of a larger ​global expansion plan ​for ​their metabolic disease portfolio. ⁣ The company ​recently secured an exclusive licensing ‌deal⁣ in Latin America, signaling a ⁣proactive approach to extending the reach of bofanglutide and⁤ other metabolic therapies ‌internationally.

Understanding GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications ​used ‌to treat type 2 diabetes. They ⁤work by mimicking the ​effects of the naturally occurring GLP-1 ​hormone, which